Analytical Regenerative Medicine Industry Framework

Dec. 9, 2013 - PRLog -- The field of regenerative medicine is very broad and encompasses many areas of scientific research and clinical applications. Until now, there was no database including all the companies of different branches of regenerative medicine, the scope of which varies from drug production on the basis of stem cells to clinical trials.

Russian scientists have offered a convenient solution to this problem (http://biogerontology.ru/files/RM_analytical_framework_2013.pdf) - a comprehensive framework, which incorporates many segments of the regenerative medicine industry and includes services, enabling technologies, cell and tissue manipulation technologies, diseases and highlights the focus on the level of organismal organization such as cells, tissue and organs. With this framework designed as a database table one can easily obtain information on available technologies, their application field and the degree of activity of the company.

While many attempts have been made to compare the various companies, research organizations and research projects, few models accounted for the whole industry supply chain and the fact that many companies participate in multiple industry segments. Some of the companies supplying reagents, equipment and cells and may have conservative growth projections and are less risky from the cash flow and clinical trials perspective, may also have basic research or translational medicine projects that may serve as major sources of growth. Likewise, companies engaged in lengthy, expensive and risky clinical trials may have research divisions working on novel research projects that may be out–licensed to other industry participants and provide stable sources of funding.

There is a vast number of Biotechnology companies and Healthcare organizations that are not commonly classified as players in regenerative medicine, but are either providing services to the industry acting as suppliers or deploying regenerative medicine technologies in the clinic creating demand. Some of the large biopharmaceutical companies often have research or translational medicine divisions that occupy leadership positions in certain industry segments are insignificant compared to the rest of the company.
To address these issues, Russian scientists developed a comprehensive Analytical Regenerative Medicine Industry Framework (ARMIF) (http://biogerontology.ru/files/RM_analytical_framework_20...), where presence of the company and level of activity in each segment is visualized using the color codes: if the company’s main business is supplying reagents and cells, the appropriate segments are highlighted in red. If the company is engaged in research of multiple cell types, but is mostly focusing on autologous cells, but also has projects using allogenic cells and is just starting the induced stem cell program, each one of these fields will be color coded by the level of activity in the field.

While ARMIF is currently limited in both, granularity and scale, it is one of the most comprehensive models for analyzing the organizations and projects in regenerative medicine that not only allows to analyze the positioning, but also evaluate the level of participation and track multiple parameters in each segment. It is a scalable and flexible platform that allows for new parameters to be added.

ARMIF represents a very ambitious attempt to further facilitate the effective analysis and comparison of the public and private companies engaged in the regenerative medicine industry.

For complete information, please visit:  biogerontology.ru/en/ (http://biogerontology.ru/files/RM_analytical_framework_2013.pdf)